These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 24387664)

  • 21. Molecularly targeted therapies for nonmelanoma skin cancers.
    Liu LS; Colegio OR
    Int J Dermatol; 2013 Jun; 52(6):654-65. PubMed ID: 23679874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cetuximab in metastatic squamous cell cancer of the skin: a Swiss case series.
    Conen KL; Fischer N; Hofbauer GF; Shafaeddin-Schreve B; Winterhalder R; Rochlitz C; Zippelius A
    Dermatology; 2014; 229(2):97-101. PubMed ID: 24923455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
    Bernier J
    Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cetuximab in squamous cell carcinoma of the head and neck.
    Hitt R; Martín P; Hidalgo M
    Future Oncol; 2006 Aug; 2(4):449-57. PubMed ID: 16922611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.
    Woo J; Palmisiano N; Tester W; Leighton JC
    Cancer; 2013 Jun; 119(11):1941-50. PubMed ID: 23504768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of cetuximab and panitumumab in oral squamous cell carcinoma cell lines: prognostic value of MAGE-A subgroups for treatment success.
    Hartmann S; Kriegebaum U; Küchler N; Lessner G; Brands RC; Linz C; Schneider T; Kübler AC; Müller-Richter UD
    J Craniomaxillofac Surg; 2013 Oct; 41(7):623-9. PubMed ID: 23375534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab.
    Bauman JE; Eaton KD; Martins RG
    Arch Dermatol; 2007 Jul; 143(7):889-92. PubMed ID: 17638733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted therapy for cutaneous oncology: a review of novel treatment options for non-melanoma skin cancer: part II.
    Walls B; Jordan L; Diaz L; Miller R
    J Drugs Dermatol; 2014 Aug; 13(8):955-8. PubMed ID: 25116974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on the Use and Treatment of Targeted Molecular Inhibitors for Locally Advanced and Metastatic Non-Melanoma Skin Cancers.
    Odueyungbo M; Ratner D
    Dermatol Surg; 2016 Jan; 42 Suppl 1():S49-56. PubMed ID: 26730974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cetuximab: still an option in the treatment of pancreatic cancer?
    Faloppi L; Andrikou K; Cascinu S
    Expert Opin Biol Ther; 2013 May; 13(5):791-801. PubMed ID: 23560505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonmelanoma skin carcinoma in Albuquerque, New Mexico: experience of a major health care provider.
    Hoy WE
    Cancer; 1996 Jun; 77(12):2489-95. PubMed ID: 8640697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
    Klinghammer K; Knödler M; Schmittel A; Budach V; Keilholz U; Tinhofer I
    Clin Cancer Res; 2010 Jan; 16(1):304-10. PubMed ID: 20028750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The emerging role of cetuximab in head and neck cancer: a 2007 perspective.
    Panikkar RP; Astsaturov I; Langer CJ
    Cancer Invest; 2008 Feb; 26(1):96-103. PubMed ID: 18181051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
    Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck.
    Kim S; Eleff M; Nicolaou N
    Head Neck; 2011 Feb; 33(2):286-8. PubMed ID: 19953623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is there a role for cetuximab in non small cell lung cancer?
    Morgensztern D; Govindan R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4602-5. PubMed ID: 17671149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.
    Zhao CY; Hwang SJE; Anforth R; Carlos G; Chou S; Carlino M; Fernández-Peñas P
    J Immunother; 2018 Sep; 41(7):343-349. PubMed ID: 29939876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
    Jedlinski A; Ansell A; Johansson AC; Roberg K
    J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.